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The development of clinical practice recommendations or guidelines for the clinical use of
biomarkers is an issue of great importance with regard to adverse drug reactions.The poten-
tial of pharmacogenomic biomarkers has been extensively investigated in recent years.
However, several barriers to implementing the use of pharmacogenomics testing exist.
We conducted a survey among members of the Spanish Societies of Pharmacology and
Clinical Pharmacology to obtain information about the perception of such barriers and to
compare the perceptions of participants about the relative importance of major gene/drug
pairs. Of 11 potential barriers, the highest importance was attributed to lack of institutional
support for pharmacogenomics testing, and to the issues related to the lack of guidelines.
Of the proposed gene/drug pairs the highest importance was assigned to HLA-B/abacavir,
UGT1A1/irinotecan, and CYP2D6/tamoxifen. In this perspective article, we compare the
relative importance of 29 gene/drug pairs in the Spanish study with that of the same pairs
in the American Society for Clinical Pharmacology andTherapeutics study, and we provide
suggestions and areas of focus to develop a guide for clinical practice in pharmacogenomics
testing.
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Functional polymorphisms of drug-metabolizing enzymes are a
major factor involved in adverse drug reactions. The develop-
ment of pharmacogenomic biomarkers has evolved in recent years,
mainly in a frame where these biomarkers are intended to be used
as outcome biomarkers, that is, to substitute for a clinical out-
come or predict an outcome of a disease or toxicity following
treatment. While the most conservative pharmacogenomics views
aim to stratify patient populations (patient selection biomark-
ers) into those who should or should not receive a given drug
(Green and Guyer, 2011), other guidelines are intended to adjust
drug dose based on pharmacogenomics tests (see for instance
Swen et al., 2011). The limitations of pharmacogenomics-based
dose adjustment are analyzed elsewhere (Agúndez et al., 2012)
and will not be discussed here, but it should emphasized that
part of the disenchantment experienced with pharmacogenomics
in recent years is related to the overoptimistic expectation of
making a safe and reliable personalized dose adjustment based
on pharmacogenomics tests. Today we know that interindividual
variability in drug metabolism and response exists, even within
individuals with identical pharmacogenomics genotypes, and so
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pharmacogenomics is simply another factor to be considered in
dose adjustment.
But in even the most conservative approaches to pharmacoge-
nomics (whether individuals would respond to a determined drug,
or what patient’s odds are to experience adverse effects with a
determined drug), many factors hamper rapid development of
the clinical use of pharmacogenomics tests. These factors have
been analyzed in detail elsewhere (Deverka et al., 2007; Haga and
Burke, 2008; Agúndez, 2009; Agúndez et al., 2009, 2012; Relling
et al., 2010; Matheis et al., 2011; Relling and Klein, 2011), but the
relative importance of these factors has received little attention.
In the frame of the Carlos III Institute of Health (ISCIII) Spanish
Research Network of Adverse Reactions to Allergens and Drugs,
we conducted a survey in 2012 among members of the Spanish
Societies of Pharmacology and Clinical Pharmacology, together
with other Spanish clinicians and geneticists closely related to
pharmacogenomics, on the most important challenges to clinical
implementation of pharmacogenomic tests. The proﬁle of the par-
ticipants was as follows: 59% were practicing physicians, 21% had
an academic research proﬁle, 16% were clinical laboratory profes-
sionals, and5%worked in thepharmaceutical industry. The survey
in Spain was designed to include the same gene/drug pairs and the
same evaluation criteria as in a US survey (Relling and Klein, 2011)
to obtain results which could be directly compared. In addition,
we included a survey regarding potential barriers to implementing
the use of pharmacogenomics testing (Agúndez et al., 2012). The
responses were closed, ranking from 1 to 10 for every item. The
ranks obtained for gene/drug pairs were re-scaled in a scale from
1 to 5 to make results comparable to those from the US survey
(Relling and Klein, 2011).
Figure 1 summarizes the results, which indicated three major
groups of barriers. The most relevant group was related to low
institutional promotion, and the second corresponded to lack of
clinical guidelines, protocols, and other factors related to validity
of pharmacogenetics tests. The barriers in this second group are
closely related to one another and, in our opinion, are a major
cause of lack of promotion and support for healthcare systems. A
third groupof barrierswith less perceived importance in the survey
was related to economical and institutional issues, knowledge of
the pharmacogenomic background of the Spanish population and
ethical, legal, or social implications.
Because most of the main barriers were related to lack of clin-
ical guidelines and protocols, we included in our survey the same
29 gene/drug pairings listed in a previous study carried out among
members of the Clinical Pharmacogenetics Implementation Con-
sortium (CPIC; see http://www.pharmgkb.org/page/cpic) and
members of the American Society for Clinical Pharmacol-
ogy and Therapeutics (Relling and Klein, 2011). The highest
ranked pairs (based on the perceived importance of the data
linking the drug to the gene variation) were HLA-B/abacavir,
UGT1A1/irinotecan, and CYP2D6/tamoxifen (Figure 2). While
most gene/drugs pairs received a similar rank in both studies,
the comparison revealed that in the Spanish study the gene pairs
CYP2C9/celecoxib and CYP2D6/nortriptyline had higher ranks
than in the US study, whereas the pairs CYP2C19/clopidogrel,
GP6D/chloroquine, and both genes related to warfarin were
ranked lower. Nevertheless, looking at the whole picture, the
ranks are similar for most gene/drug pairs, thus indicating that
guidelines for gene/drug pairs such as those which are cur-
rently being elaborated by CPIC members seem to be well suited
for Spain, and probably for other European countries with
a similar genetic background. The few discrepancies observed
in Figure 2 may be related to the differences in the pattern
of drug use in the US and in Spain. CPIC guidelines on
some of the gene/drug pairs mentioned have already been pub-
lished (see for instance (Johnson et al., 2011; Crews et al., 2012;
Wilke et al., 2012) and many others are currently underway (see
http://www.pharmgkb.org/page/cpicGeneDrugPairs). Hopefully
FIGURE 1 | Highest-ranking barriers to implementing the use of
pharmacogenomics testing, based on a survey of Spanish Societies for
Pharmacology and Clinical Pharmacology members in 2012. Data related
to average importance (on a scale of 1–10) are plotted along the x -axis.
Frontiers in Genetics | Pharmacogenetics and Pharmacogenomics November 2012 | Volume 3 | Article 273 | 2
“fgene-03-00273” — 2012/11/22 — 15:31 — page 3 — #3
Agúndez et al. Factors which hamper biomarker use
FIGURE 2 | Highest-ranking gene/drug pairs, based on a survey of Spanish Societies for Pharmacology and Clinical Pharmacology members in 2012
(blue bars), compared to a published survey of American Society for Clinical Pharmacology andTherapeutics (ASCPT) members conducted by CPIC
(red bars). Data related to the percentages of respondents who ranked the gene/drug pairs as 1 or 2 (on a scale of 1–5) are plotted along the y -axis.
we will soon have guidelines available for all relevant gene/drug
pairs.
Nevertheless, some remaining questions related to intereth-
nic and intraethnic genetic variability (Garcia-Martin et al., 2006;
Garcia-Martin, 2008; Borobia et al., 2009; Restrepo et al., 2011),
reﬁnement in phenotype inference (Agúndez et al., 2008; Ruiz
et al., 2012), and detailed studies on the contribution of additional
factors which may modify the strength of the association of
gene/drugs pairs need to be dealt with. These studies should
include gene expression and regulation, patient’s metabolic pro-
ﬁle with a given drug, and relevant lifestyle and environmental
factors that inﬂuence drug metabolism or drug response. Once
guidelines and protocols are ready, the major groups of barriers
shown in Figure 1 will be weakened. And, in consequence, this
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will hopefully lessen the impact of the ﬁrst and most determinant
barrier, since we believe that institutional support and promotion
for the use of pharmacogenomics biomarkers will greatly improve
as the inﬂuence of the other barriers decline.
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